返回

Amarin highlights ESC 2026 evidence supporting icosapent ethyl

正在验证中
  • Amarin highlighted ESC 2026 presentations on IPE, EPA and residual cardiovascular risk.
  • 2026 ESC guidelines recognized REDUCE-IT RENAL evidence of reduced major cardiovascular events with IPE.
  • Amarin said risk reductions were consistent across baseline eGFR subgroups, with larger absolute benefits at lower eGFR.
本网站上的信息是使用AI生成的，我们无法保证其准确性。 请仅作为参考信息使用。